Elan sees 2003 total revenue drop by a third

Pharmaceutical giant Elan has reported that total revenue for 2003 fell 34% on 2002's figure, to $746m (€578.59m).

Revenue from retained products (excluding Zanaflex which went generic in June 2002) was up 41% at $398.4m (€308.98m).